metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
ovarian cancer (OC) ovarian cancer (OC)
mOC - L1 - all population metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - all population
versus placebo plus SoC
	atezolizumab plus SoC vs. placebo plus SoC	1	0.96 [0.74; 1.25], 1 RCT, I2=0% inconclusive result	0.92 [0.79; 1.07], 1 RCT, I2=0% inconclusive result	-
mOC - L1 - PDL1 positive metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - PDL1 positive
versus placebo plus SoC
	atezolizumab plus SoC vs. placebo plus SoC	1	0.98 [0.68; 1.41], 1 RCT, I2=0% inconclusive result	0.80 [0.65; 0.99], 1 RCT, I2=0% unassessable degree of certainty	-
metastatic/advanced OC (mOC) - 2nd line (L2) metastatic/advanced OC (mOC) - 2nd line (L2)
metastatic/advanced OC (mOC) - maintenance (M) metastatic/advanced OC (mOC) - maintenance (M)